NCT02089932View on ClinicalTrials.gov

Dexmedetomidine in Different Dose Levels as Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

June 30, 2015

Conditions
DexmedetomidineFemoral Nerve BlockArthroscopic Knee Surgery
Interventions
DRUG

peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block

"ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia."

DRUG

Placebo

Trial Locations (1)

11562

Kasr Al Ainy, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT02089932 - Dexmedetomidine in Different Dose Levels as Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block. | Biotech Hunter | Biotech Hunter